Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme
Principal Investigator
Andrew Lassman, MD
Status
Terminated
Date Opened To Accrual
January 24 2007
Date Closed to Accrual
March 22 2011
Date of Study Termination
September 04 2018
Disease Site
Brain [BN]
Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine the therapeutic efficacy of dasatinib in all patients (i.e., stages 1B and 2 combined) with recurrent/progressive GBM as measured by 6-month progression-free survival.
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Patients with GBM who have progressive/recurrent disease despite treatment with radiotherapy and temozolomide. Patients accrued to stage 1 (closed to accrual) or stage 1B (opened to accrual May 5, 2009) require overexpression/activity in at least two of the following SRC, KIT, PDGFR, and EPHA2. Patients accrued to stage 2 (cohort closed; not currently applicable) do not require overexpression/activity.
Target Accrual
84
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.